![](https://endpts.com/wp-content/uploads/2022/07/Michael-Davidson-NewAmsterdam-via-Caladrius-tile.jpg)
Michael Davidson, NewAmsterdam CEO
NewAmsterdam's bid to revive Amgen cardio drug heads to Nasdaq in Frazier SPAC deal
Five years after Amgen buried its CETP cholesterol drug, a Dutch biotech with hundreds of millions in funding is headed to Wall Street to continue …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.